Nrx Pharma Seeks Us Fda Breakthrough Therapy Status For Zyesami In Patients At Immediate Risk Of Death From Covid-19 Despite Treatment With Remdesivir And Other Approved Therapies

Nrx Pharmaceuticals Announced Today That It Has Filed A New Breakthrough Therapy Designation (Btd) Request With The Us Food And Drug Administration (Fda) Focused On Patients With Critical Covid-19 And Respiratory Failure Who Are At Immediate Risk Of Death Despite Treatment With Remdesivir And Other Approved Therapies.Nrx Filed The Request After The Fda